Nucleic acid therapeutics as differentiation agents for myeloid leukemias
O Kovecses, FE Mercier, M McKeague - Leukemia, 2024 - nature.com
Differentiation therapy has proven to be a success story for patients with acute promyelocytic
leukemia. However, the remaining subtypes of acute myeloid leukemia (AML) are treated …
leukemia. However, the remaining subtypes of acute myeloid leukemia (AML) are treated …
miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34 + cells partially via SERPINE1
X Zhang, W Ma, W Xue, Y Wang, P Chen, Q Li… - Cellular and Molecular …, 2024 - Springer
The formation of the BCR-ABL fusion gene drives human chronic myeloid leukemia (CML).
The last 2 decades have witnessed that specific tyrosine kinase inhibitors (TKIs, eg, imatinib …
The last 2 decades have witnessed that specific tyrosine kinase inhibitors (TKIs, eg, imatinib …
Delivery Aspects for Implementing siRNA Therapeutics for Blood Diseases
S Abbasi Dezfouli, ME Michailides, H Uludag - Biochemistry, 2024 - ACS Publications
Hematological disorders result in significant health consequences, and traditional therapies
frequently entail adverse reactions without addressing the root cause. A potential solution for …
frequently entail adverse reactions without addressing the root cause. A potential solution for …